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Worm transplantation studies show that physiological and reproductive status of
the worm is influenced by the microenvironment of the host and critical for vaccine design.
Wormmigration studies in rats with 75Se-methionine labeled cercariae demonstrated that
resistance to reinfection (R/R) requires a host immune response resulting in worm death.
In permissive hosts, inflammation due to anti eggs immunity leads to host death, whereas
in non-permissive hosts this is not the case due to reduced egg burdens. Eggs-induced
pathology and inflammatory debris resulting from immune attack on worms are important
for vaccine design. Protective immune responses are perhaps induced when naïve
hosts are vaccinated with either schistosome-derived molecules or attenuated cercariae
as suggested by the induction of protective anti-parasite antibodies and monoclonals.
However, these immunological strategies rarely produce 85–90% R/R as is achievable by
portal-caval shunting. Alternatively, induction of anti-schistosoma immunity may induce
portacaval shunting, seems highly unlikely although not yet tested. Differential screening
with sera from twice-infected rats, protective (F2x) from Fisher vs. non-protective (W2x)
from Wistar–Furth rats, was used to identify candidate vaccine antigens.
Keywords: S. mansoni, portacaval shunt, self-cure, resistance-to-reinfection, F2x (sera from twice-infected Fisher
rats), W2x (sera from twice-infected Wistar–Furth rats), permissive vs. non-permissive hosts
Background
The authors’ combined research careers of over 60 years has focused on a preventive vaccine
against schistosomiasis. In 1970 while Dr. Knopf was a postdoctoral fellow at the Salk Institute
(California), Harvard physicist John Platt, then incumbent “Scientist In Residence,” presented a
seminar entitled “What We Must Do”(1). Platt focused on the disparity between the funding and
scientific resources invested on diseases of wealthier longer-lived populations such as: obesity,
cancer, diabetes, and ischemic heart disease compared to diseases of the poor such as bacterial/viral
and parasitic infections. Moreover, interests in anti-Vietnam war, woman’s lib, and racial inequality
were also predominant in that era. So, emotionally moved and stimulated by Platt’s seminar, a group
of young scientists and technicians formed study groups to explore their knowledge and potential of
immunology to address this huge disparity. Topics chosen included birth control, food distribution,
and infectious diseases such as schistosomiasis, malaria, and hookworm. Dr. Knopf, along with Alan
Sher, Donato Cioli, and Italo Cesari, became further interested in schistosomiasis and in particular
with the work of R. Smithers, R. Terry, and J. Clegg on in vitro culturing of Schistosoma worms
(2). After visiting the schistosome research laboratory of A. MacInnis at UCLA, Dr. Knopf accepted
a faculty position at Brown University in the Department of Molecular Biology and Immunology.
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Dr. Alferd Senft, an established researcher in the field of schis-
tosomiasis with connections to the Rockefeller Foundation, was
already a faculty member at Brown. Dr. Knopf started his research
career in schistosomiasis in 1972.
At Brown, Dr. Knopf set-up the Schistosoma mansoni life cycle
and learned to perform animal infections with help from Don
Harn and F. von Lichtenberg (both at Harvard). Dr. Suri joined
the laboratory in 1982 and her dissertation focused on differential
screening and recombinant DNA technology to identify candi-
date vaccine protein antigens of S. mansoni. After completing
postdoctoral training in liver cirrhosis, she rejoined Dr. Knopf ’s
laboratory as an assistant professor and continued research on
the identification of T-cell epitopes on a S. mansoni candidate
vaccine antigen using overlapping peptides and a novel prediction
algorithm (3).
Results
Dr. Knopf ’s initial schistosome study (supported by Rockfeller)
was an attempt to repeat data from mice (permissive hosts), in
rats (non-permissive hosts). In rats, S. mansoni does not complete
its life cycle (no eggs in stool, no worms in mesenteric veins)(4).
Rats developed R/R, which was dependent on cercarial dose used
in challenge infections (5). Both at 50 and 500 cercariae used
for primary infection, there was significant R/R. At a primary
and challenge dose of 500 cercariae/rat, there was significant R/R
of 50%, but at the higher challenge dose of 5000 cercariae, no
further increase in R/R was observed. We speculated this was
due to either induction of immune tolerance or saturation of
immune capacity by the secondary infection. In mice, however,
a dose of 50 cercariae was lethal in <2months; interestingly, a
dose as high as 5000 cercariae/rat induced no morbidity at all. At
4weeks post infection, worm yields by portal perfusion of once
infected rats are maximal and so is their size. From weeks 4 to
8, worm attrition occurs with minimal worm pairing, low egg
production, and poor embryo maturation to miracidia. About
50–60% of cercariae achieve this immature state, as confirmed
by the use of radiolabeled worms (6). In mice, worms continue
to grow rapidly until 6 weeks, with pairing occurring earlier and
female worms laying eggs. The number of eggs is far fewer in
infected rats as is worm yield and pairing by 6weeks (~10% of
mouse yields). We developed a modified assay to collect lung-
stage worms, adding HEPES (7) before incubation of minced
lungs, in order to neutralize acid generated by both worms and
inflammatory responses in infected minced lung tissue. Increased
somule yields were found and thus we confirmed data from mice
studies (8) in rats. While worm yields increased, the percent R/R
decreased from 80–90% to 50–60%.
Dr. Cioli spent a year in Dr. Knopf ’s laboratory and they
performed a unique series of worm transfer experiments. They
assessed the survival, growth, and egg laying capacity of S.mansoni
worms surgically transplanted from mice (permissive hosts) into
rats (non-permissive hosts) or from rats to hamsters (permissive
hosts) (4). Following transplantation into rats, adultmouse worms
regress in size, remain in the liver, and produce small numbers
of incompletely developed eggs. Conversely, transplantation of
rat worms to hamster, worms increase in size, localize in the
mesenteric veins, and produce numbers of eggs approaching nor-
mal hamster-grown worms within 3weeks. These studies indicate
that the physiological and reproductive status of the worm is
strongly influenced by themicroenvironment of the host. Further-
more, the suppression of worm growth and egg laying capacity in a
non-permissive host is a reversible phenomenon since on transfer
into a permissive environment; stuntedworms can resume growth
and oviposition.
In collaboration with Cioli, Mangold, and Dean (6), para-
site migration was studied using 75Se-methionine radiolabeled
cercariae obtained by exposing previously infected snails to the
tracer a day prior to shedding. Infected snails take up >90% of
radiolabeled methionine analog in 12 h thus resulting in labeled
cercariae, which were then used to infect groups of young rats
(~120 g). On day 0, animals received normal Fisher rat serum
(FNRS) or serum from twice-infected Fisher rats (F2x). Over the
next few days, abdominal skin (infection site), as well as lung
and liver tissue, was removed. Autoradiographic analysis of the
pressed tissue revealed that the number of liver foci observed
were nearly equal to the number of worms collected by portal
perfusion (Figures 1A,B). Results confirmed that ~70% of applied
cercariae attached to skin. Within 3–5 days, parasites migrated
from skin to lungs with high efficiency in both normal and
passively immunized rats. The total number of labeled parasites
detected in skin, lungs, and liver was constant through day 5,
declined to about 60% of this value by day 11 in both groups.
Over the next 10 days, the rate of decline decreased significantly
in normal rats, but did not change in immune rats. By day 21 post
infection, nearly 50% fewer foci (labeled parasites) were detectable
in livers of immune rats. The kinetics of migration from lungs
to the liver differed in the two groups. In passively immunized
rats with F2x, the parasites are trapped in the lungs longer as
evidenced from the increased number of foci in lungs (Figure 1B).
In other words, the disappearance of labeled parasites from the
lungs was delayed in passively immunized rats. Labeled parasites
accumulated in the liver, reaching maximal values by 11 days post
infection in both groups, and remaining constant through day
21. However, half the numbers of labeled parasites were in liver
of immune rats. We conclude that a subpopulation of parasites
in the lungs is the target of protective immunity conferred by
the F2x serum used for passive immunization. Target parasites,
retained longer in lungs, were probably prevented frommigrating
successfully to the liver. Another parasite subpopulation migrated
to the liver with normal kinetics, but was shunted out of the liver
pathway and was lost forever.
Next, lung schistosomula isolated from both FNRS and F2x
passively immunized rats were transferred by intravenous injec-
tion into naïve recipient rats and their continued migration from
lungs to liver compared. Similar worm yields by portal perfusion
from FNRS or F2x recipients were noted. We conclude that the
effects of immunity molecules in F2x on somules during 1week
post infection were insignificant or reversible.
Another interpretation of the worm transfer studies could indi-
cate a defect in worm sexual maturation in rats (6, 9). Perhaps in
permissive host species, there exists a host hormone that binds to a
sex-hormone receptor present in worms, but this is accomplished
poorly in rats. The hormone produced by rats could partially
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FIGURE 1 | (A) Distribution of auto radiographic foci in normal rats
at various time post infection. Rats were exposed to 200 75Se-
Selenomethionine-labeled cercariae on day 0. The mean number of auto
radiographic foci numerated from two separate experiments are plotted.
(B) Distribution of auto radiographic foci at various time post infection in
normal and day 5 passively immunized rats. Rats were exposed to 200
75Se-Selenomethionine-labeled cercariae on day 0 and a subgroup was
passively immunized with F2x on day 5 post infection. The mean numbers
of auto radiographic foci numerated from two separate experiments are
plotted.
inhibit worm maturation was studied by removal of pituitary
(hypophysectomy or HYPOX) and then by removal of gonads,
ovaries, thyroid, or adrenal glands. These rats were then infected
with cercariae. Major finding was that worm yields and matura-
tion improved in both HYPOX and in THYROX rats (10, 11).
Thus, some step in thyroid hormonemetabolism created limits on
schistosome maturation and survival (Table 1).
The miracidia hatched from eggs produced in cercariae-
infected THYROX rats were incubated with snails and a month
later, shed cercariae collected and used to infect normal mice.
About 4–6weeks later, worms had paired and produced viable
eggs. This is a Koch-like proof of the conclusion that the T3 is
likely to generate, or be the source of, the inhibition of worm
maturation in a non-permissive host.
During Dr. Knopf ’s sabbatical leave in D. McLaren’s labora-
tory at Mill Hill (UK), in collaboration with G. Mitchell, worm
migration was studied in inbred 129 strain of mice. Interestingly,
although a permissive host, some of the inbred 129 strain of mice
did not yield adult worms when infected with cercariae. Assessed
at 8–10weeks, the somules had moved from skin to lungs but
failed to migrate to the portal circulation, and thus could not be
collected by portal perfusion. Some worms were found in the lung
capillaries involved with eosinophils. Concurrently, A.Wilson and
P. Coulson described the “leaky liver” phenomenon that pre-
existed in some of these 129 strain mice and was independent of
infection. This was an anatomical anomaly of blood vessels that
failed to yield properly located adult worms. We published our
results in separately submitted papers (12, 13).
Next, our concerted efforts were focused on the use of dif-
ferential screening to identify candidate vaccine antigens exclu-
sively binding with antibodies in protective F2x but absent in
non-protective W2x sera. A tegumental glycoprotein Sm25 was
identified as a candidate vaccine antigen and corresponding gene
(GP22) cloned. Codons 43–182 amplified by PCR and cloned in
pET15b bacterial expression system. Recombinant protein r140,
in combination with different adjuvants, was tested for its vacci-
nation potential. We vaccinated mice and rats with recombinant
products (3, 14–16). Despite high titer anti-r140 antibodies with
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TABLE 1 |Normal (4–8 rats) or THYROX (6 rats) per group were infected at 270 cercariae/rat and maintained daily without thyroid hormone or with T3 or T4.








Sex ratio (m/f) Weight gain
(g/week)
Normal 4weeks (5) 19:2 9.6 9.4 1:0
5weeks (6–8) 41:7
6weeks (4) 10:5 4.5 6.0 0:75
7weeks (6) 6:3 1.8 4.5 0:4
Thyrox 7weeks (6) 16:3 7.8 8.5 0:9 8:9
Thyrox+ T3 7weeks (6) 5:3 2.2 3.2 31:3
Thyrox+ T4 7weeks (6) 1:5 0.8 0.7 0:8 27:8
Weighed weekly. Worms collected: number, length (mm), gender scored.
protective isotypes that detected a 25 kDa surface antigen, no
protection against subsequent cercarial challenge or any effect on
egg yield was observed. This has led us to conclude that not all
molecules produced by worms are candidate target sites. How-
ever, the differential screening technique we developed in iden-
tifying candidate vaccine antigens has proven useful in another
widespread tropical disease, malaria (17).
Conclusion
After a combined research career of 60 years, we strongly believe
that we now understand something new about schistosome infec-
tion. Our research sheds light on the importance of host microen-
vironment in parasite attrition. Schistosomes have an enormous
host range including several mammalian species such as, man
and some primates, as well as rodents, and other phyla (snails
for miracidia). Man and mouse appear to be good examples of
permissive primary hosts (after infection with cercariae, viable
eggs are found in feces); while Rattus norvegicus rats appear to
be non-permissive hosts as cercarial infection results in absence
of viable eggs in feces. Then, there are transient or temporary
permissive hosts (permissive initially but subsequently become
non-permissive) such as rhesus macaque, guinea pigs, and Rattus
rattus (water rat, black rat). 129 strain mice are mixed. These
“Transient permissive” hosts become that way by acquiring, e.g.,
portacaval shunts (before or during infection) or self-curing a
primary infection. Also thyroidectomy can convert the rats from
non-permissive to permissive state. Therefore, it seems appro-
priate to categorize the host in the vaccination study accord-
ingly and be aware of the host defense mechanisms in vaccine
objective.
In conclusion, one can predict two ways to end an infection by
schistosoma parasites: either via immune attack or via portacaval
shunting. Rats do both, before worms can form pairs, whereas
others such as: mice, some monkey strains, and guinea pigs take
longer before becoming non-permissive hosts and eliminating
the parasites. Hence, the latter can be classified as conditionally
permissive. The thyrox R. norvegicus rat should likely be classified
as conditionally or transiently permissive.
Great leaps have been made toward schistosomiasis vaccine
in the past decade, reviewed in Ref. (18–22). Calpain (Sm-p80)
stands out as protective vaccine with cross species specificity,
and already been tested as recombinant vaccine (hamsters and
mice with Abs longevity 60weeks in mice) and as DNA vaccine
(baboons-Abs detected 5–8 years post vaccination). Coupled with
purification to homogeneity, Sm-p80 is ready to be manufactured
with GMP practices for clinical trials (23). Detection and testing
of schistosome gut antigens related to nutrient uptake as potential
vaccines is exciting (24). Use of nanoparticle gene delivery (25)
and design of conformational and self-adjuvinating epitopes (26,
27) have taken the field of vaccine development to new levels.
With the advances in Bioinformatics, availability of proteomic and
genomic databases (28), a vaccine in the next decade could be
a reality. While not identical to cases of pneumococcal bacterial
or poliovirus infection, where multivalent vaccines resulted in
successful vaccine, parasitic infections lead to multiple forms of
the infectious agent: larval, juvenile, adult male and female worm,
eggs etc., displaying unique and shared epitopes. Cocktail vaccines
combining target antigens unique to different life cycle stages
might give an additive protection. As pointed out by McManus
and Loukas (18), putative resistant (PR) – a well defined cohort
of individuals in Brazil, who display natural resistance to schisto-
some infection despite years of exposure to S. mansoni, should be
studied further. They might hold a clue and give new insight to
vaccine development.
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